- Primary extranodal classical Hodgkin lymphoma (PE-cHL) is associated with significantly shorter remission, increased chance of relapse, and inferior survival vs primary nodal Hodgkin lymphoma (PN-cHL).
- Elevated lactate dehydrogenase (LDH) and platelets (PLT) are prognostic of inferior PFS (P<.05>
Why this matters
- Data are scarce regarding this patient subpopulation.
- Study to investigate clinical characteristics in 22 patients with PE-cHL vs 274 control patients with PN-cHL.
- 68.2% of patients had stage IV disease.
- Median patient age, 30 (range, 15-69) years.
- Funding: National Natural Science Foundation of China; Beijing Natural Science Foundation; others.
- Initial PE-cHL symptoms were generally associated with originating site of disease, but not painless superficial lymph node enlargement.
- 86.4% received ABVD (adriamycin, bleomycin, vincristine, and dacarbazine).
- 9.1% received BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone).
- 42.4% 5-year PFS in patients with PE-cHL vs 82.2% with PN-cHL (log rank=18.775; P=.000).
- 36.4% incidence of relapse or progression in patients with PE-cHL vs 13.1% with PN-cHL (P=.003).
- 64.6% 5-year OS in patients with PE-cHL vs 97.7% with PN-cHL (log rank=11.485; P=.001).
- Elevated LDH and elevated PLTs were both prognostic of inferior PFS in PE-cHL (P<.05>
- Retrospective data.